Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy

Medical Oncology

Volumn 31, Issue 12, 2014, Pages 1-6

  Hedenus, Michael ^a   Karlsson, Torbjörn ^b   Ludwig, Heinz ^c   Rzychon, Beate ^d   Felder, Marcel ^d   Roubert, Bernard ^d   Birgegård, Gunnar ^b  

^a SUNDSVALL HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c WILHELMINEN HOSPITAL   (Austria)

^d Vifor (International) Inc   (Switzerland)

Author keywords

Anemia; Ferric carboxymaltose; Functional iron deficiency; Intravenous iron; Lymphoid malignancies

Indexed keywords

ANTINEOPLASTIC AGENT; FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; TRANSFERRIN; FERRIC ION; MALTOSE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHEMOTHERAPY INDUCED ANEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; FUNCTIONAL IRON DEFICIENCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANEMIA; ANEMIA, IRON-DEFICIENCY; CHEMICALLY INDUCED; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANEMIA, IRON-DEFICIENCY; ANTINEOPLASTIC AGENTS; FEMALE; FERRIC COMPOUNDS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MALTOSE; MIDDLE AGED; MULTIPLE MYELOMA; TREATMENT OUTCOME;

EID: 84919909213     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0302-3     Document Type: Article

References (17)

1. Ludwig H, Muldur E, Endler G, Hubl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol. 2013;24(7):1886–92.
2. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001;91(12):2214–21.
3. Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of intravenous iron. Ann Oncol. 2012;23(8):1954–62.
4. Andrews NC. Forging a field: the golden age of iron biology. Blood. 2008;112(2):219–30.
5. Ludwig H, Aapro M, Bokemeyer C, Glaspy J, Hedenus M, Littlewood TJ, et al. A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer. 2014;22(8):2197–206.
6. Ludwig H, Aapro M, Bokemeyer C, MacDonald K, Soubeyran P, Turner M, et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the anaemia cancer treatment (ACT) study. Eur J Cancer. 2009;45(9):1603–15.
7. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Erythropoietin or Darbepoetin for patients with cancer–meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009; 3:CD007303.
8. Spahn DR, Moch H, Hofmann A, Isbister JP. Patient blood management: the pragmatic solution for the problems with blood transfusions. Anesthesiology. 2008;109(6):951–3.
9. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008;168(21):2377–81.
10. National Comprehensive Cancer Network Inc. NCCN practice guidelines in oncology: cancer and chemotherapy-induced anemia - v.2.2015. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive.
11. Gafter-Gvili A, Steensma DP, Auerbach M. Should the ASCO/ASH Guidelines for the use of intravenous iron in cancer- and chemotherapy-induced anemia be updated? J Natl Compr Cancer Netw. 2014;12(5):657–64.
12. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol. 2010;116(3):522–5.
13. Athibovonsuk P, Manchana T, Sirisabya N. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol Oncol. 2013;131(3):679–82.
14. Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, Kim SH, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol. 2007;105(1):199–204.
15. Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 2013;24(2):475–82.
16. Abdel-Razeq H, Abbasi S, Saadi I, Jaber R, Abdelelah H. Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study. Drug Des Dev Ther. 2013;7:939–44.
17. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007;43(2):258–70.